Fused bicyclic oxazolidinone CETP inhibitor
US8871738B2 · kind B2 · utility
8Cited by
0References
60Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 25, 2012 |
| Grant date | Oct 28, 2014 |
| Priority date | — |
| Expiry date | Oct 25, 2032 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.